Literature DB >> 18245565

Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.

Arintaya Phrommintikul1, Lavinia Tran, Andrew Kompa, Bing Wang, Anastasia Adrahtas, Danielle Cantwell, Darren J Kelly, Henry Krum.   

Abstract

The RhoA-Rho kinase (ROCK) signaling pathway has an important role in cardiovascular diseases. However, the effect of Rho kinase inhibition on pressure overload-induced cardiac hypertrophy (POH) and associated diastolic dysfunction has not been evaluated. This study examined the effect of a selective ROCK inhibitor (GSK-576371) in a POH model, induced by suprarenal abdominal aortic constriction. POH rats were divided into the following four groups: 1 (GSK 1, n = 9) or 3 (GSK 3, n = 10) mg/kg bid GSK-576371, 1 mg.kg(-1).day(-1) ramipril (n = 10) or vehicle (n = 11) treatment for 4 wk. Sham animals (n = 11) underwent surgery without banding. Echocardiograms were performed before surgery and posttreatment, and hemodynamic data were obtained at completion of the study. Echocardiography showed an increase in relative wall thickness of the left ventricle (LV) following POH + vehicle treatment compared with sham animals. This was attenuated by both doses of GSK-576371 and ramipril. Vehicle treatment demonstrated abnormal diastolic parameters, including mitral valve (MV) inflow E wave deceleration time, isovolumic relaxation time, and MV annular velocity, which were dose dependently restored toward sham values by GSK-576371. LV end diastolic pressure was increased following POH + vehicle treatment compared with sham (6.9 +/- 0.7 vs. 3.2 +/- 0.7 mmHg, P = 0.008) and was reduced with GSK 3 and ramipril treatment (1.7 +/- 0.7, P < 0.01 and 2.9 +/- 0.6 mmHg, P < 0.01, respectively). Collagen I deposition in the LV was increased following POH + vehicle treatment (32.2%; P < 0.01) compared with sham animals and was significantly attenuated with GSK 1 (21.7%; P < 0.05), GSK 3 (23.8%; P < 0.01), and ramipril (35.5%; P < 0.01) treatment. These results suggest that ROCK inhibition improves LV geometry and reduces collagen deposition accompanied by improved diastolic function in POH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18245565     DOI: 10.1152/ajpheart.01078.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  43 in total

Review 1.  Rho kinases in cardiovascular physiology and pathophysiology: the effect of fasudil.

Authors:  Jianjian Shi; Lei Wei
Journal:  J Cardiovasc Pharmacol       Date:  2013-10       Impact factor: 3.105

Review 2.  Cell type-specific signaling function of RhoA GTPase: lessons from mouse gene targeting.

Authors:  Xuan Zhou; Yi Zheng
Journal:  J Biol Chem       Date:  2013-11-07       Impact factor: 5.157

Review 3.  Therapeutic approaches to diastolic dysfunction.

Authors:  Rajesh Janardhanan; Akshay S Desai; Scott D Solomon
Journal:  Curr Hypertens Rep       Date:  2009-08       Impact factor: 5.369

Review 4.  Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs.

Authors:  Tiago Fernandes; Valério G Baraúna; Carlos E Negrão; M Ian Phillips; Edilamar M Oliveira
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-06-12       Impact factor: 4.733

5.  Alterations in cardiac structure and function in a modified rat model of myocardial hypertrophy.

Authors:  Wen-Jun Dai; Qi Dong; Min-Sheng Chen; Lu-Ning Zhao; Ai-Lan Chen; Zhen-Ci Li; Shi-Ming Liu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-10-16

Review 6.  Myocardial transcription factors in diastolic dysfunction: clues for model systems and disease.

Authors:  Alexander T Mikhailov; Mario Torrado
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

7.  Sirtuin 1 represses PKC-ζ activity through regulating interplay of acetylation and phosphorylation in cardiac hypertrophy.

Authors:  Jingyan Li; Junying Huang; Jing Lu; Zhen Guo; Zhuoming Li; Hui Gao; Panxia Wang; Wenwei Luo; Sidong Cai; Yuehuai Hu; Kaiteng Guo; Luping Wang; Zhenzhen Li; Minghui Wang; Xiaolei Zhang; Peiqing Liu
Journal:  Br J Pharmacol       Date:  2018-12-09       Impact factor: 8.739

Review 8.  Rho kinase as a therapeutic target in cardiovascular disease.

Authors:  Michelle Surma; Lei Wei; Jianjian Shi
Journal:  Future Cardiol       Date:  2011-09

9.  Prevention of RhoA activation and cofilin-mediated actin polymerization mediates the antihypertrophic effect of adenosine receptor agonists in angiotensin II- and endothelin-1-treated cardiomyocytes.

Authors:  Asad Zeidan; Xiaohong Tracey Gan; Ashley Thomas; Morris Karmazyn
Journal:  Mol Cell Biochem       Date:  2013-10-06       Impact factor: 3.396

10.  The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling.

Authors:  Dongwu Lai; Jing Gao; Xukun Bi; Hong He; Xiaolu Shi; Shaoxiang Weng; Yu Chen; Ying Yang; Yang Ye; Guosheng Fu
Journal:  J Mol Med (Berl)       Date:  2016-08-30       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.